Synonyms: CTP-543 | CTP543 | D8-ruxolitinib | Leqselvi®
deuruxolitinib is an approved drug (FDA (2024))
Compound class:
Synthetic organic
Comment: Deuruxolitinib (CTP-543) is a deuterium-modified analogue of the JAK inhibitor ruxolitinib. It is an oral inhibitor that inhibits JAK1/2. The chemical structure, and its use in hair loss disorders are claimed in patent WO2017192905A1 [3].
|
|
Immunopharmacology Comments |
JAK inhibition inhibits the defective activation of the JAK/STAT pathway that is involved in the pathogenesis of alopecia areata, and this action reverses T cell-mediated inflammatory hair loss and nail dystrophy in AA patients. |